Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening.

Key facts

Study ID

NCT07571161

Run by

Eli Lilly and Company

People needed

140

Starts

2026-04-30

Expected to finish

2030-04-01

Last updated by the study team

2026-08-06

Who can join

Age: 55 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A Telephone Interview for Cognitive Status - Modified (TICS-M) score indicative of intact cognitive function (cut-off score of 35 or higher)
• Clinical Dementia Rating-Global Score (CDR-GS) of 0
• A plasma P-tau result consistent with amyloid pathology
• A reliable study partner who:
• Provides written informed consent to participate in the study in their role
• Has frequent contact with the participant and is familiar with their overall function and behavior, including daily activities and cognitive abilities
• Is of legal age (18 years of age or older) to consent
• Is available to conduct functional scales
• Have adequate literacy, vision, and hearing for neuropsychological testing

You may not qualify if…

• Have mild cognitive impairment (MCI), dementia, or other significant neurodegenerative diseases that could affect cognition
• Have a serious or unstable illness (including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease, or other condition) that, in the investigator's opinion, could interfere with study analyses or result in a life expectancy of 5 years or fewer
• Have received active or passive immunization against amyloid beta (Aβ) in any other study
• Have current or prior use of prescription medications for treatment of MCI or AD
• Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants or other accessory medical devices, such as cardiac pacemakers, stents, and cochlear implants
• Have a centrally read magnetic resonance imaging (MRI) demonstrating the presence of Amyloid-related imaging abnormalities (ARIA-E), more than 4 cerebral microhemorrhages, more than 1 area of cortical superficial siderosis, any macrohemorrhage (that is, intracerebral hemorrhage more than 1 cm), or severe white matter disease at screening

Where it is running

• Zunyi First People's Hospital — Zunyi, China (enrolling)
• The First Hospital of Jilin University — Changchun, China (enrolling)
• Xiangya Hospital Central South University — Changsha, China (enrolling)
• Sichuan Provincial People's Hospital — Chengdu, China (enrolling)
• Qinghai Provincial People's Hospital — Xining, China (enrolling)
• Zigong First People's Hospital — Zigong, China (enrolling)
• Peking University Third Hospital — Beijing, China (enrolling)
• Guangdong Provincial People's Hospital — Guangzhou, China (enrolling)
• Anhui Provincial Hospital — Hefei, China (enrolling)
• The Second Hospital of Jiaxing — Jiaxing, China (enrolling)
• Jinan Central Hospital — Jinan, China (enrolling)
• The Second Affiliated Hospital of Nanchang University — Nanchang, China (enrolling)
• Jiangsu Province Official Hospital — Nanjing, China (enrolling)
• Nanjing Brain Hospital — Nanjing, China (enrolling)
• Sir Run Run Hospital of Nanjing Medical University — Nanjing, China (enrolling)
• The First Affiliated Hospital of Nanyang Medical College — Nanyang, China (enrolling)
• Shanghai Sixth People's Hospital — Shanghai, China (enrolling)
• Shanghai East Hospital — Shanghai, China (enrolling)
• Renji Hospital Shanghai Jiao Tong University School of Medicine — Shanghai, China (enrolling)
• Huashan Hospital, Fudan University — Shanghai, China (enrolling)
• Pudong New Area People's Hospital Shanghai — Shanghai, China (enrolling)
• ShenZhen People's Hospital — Shenzhen, China (enrolling)
• The First Hospital of Hebei Medical University — Shijiazhuang, China (enrolling)
• Tianjin Medical University General Hospital — Tianjin, China (enrolling)
• The First Affiliated Hospital of Wenzhou Medical University — Wenzhou, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.